Investigating an Off-The-Shelf, Disease Agnostic, Tumour Specific, Patient-Specific Neo-antigen Cancer Vaccine

Time: 2:30 pm
day: Conference Day Two

Details:

  • Summarising the development of a universal solid tumour cancer vaccine
  • Analysing the priming phase shifts Th1/Th2 balance and how the activation phase converts “cold’ tumours to “hot”
  • Showcasing recent clinical results

Speakers: